Covista Inc. (CVSA)
Quantitative Summary
DeterministicAt 17.0x earnings — a 48% discount to the sector average of 32.6x — CVSA is in the lower valuation range. Financial health metrics are strong: Piotroski 7/9, Altman Z 4.3 (above 3.0 safe zone threshold).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of this consumer defensive operator demonstrate a robust spread between capital efficiency and cost of equity, with an ROIC-WACC margin of +3.3% indicating value creation above the hurdle rate. The DuPont decomposition reveals that earnings quality is primarily driven by exceptional profitability rather than leverage or asset turnover; specifically, a net margin of 13.3% sits atop a commanding gross margin of 56.9%, suggesting strong pricing power within its niche. Financial integrity metrics further support this profile: the high Piotroski F-Score of 7/9 signals improving fundamentals and balance sheet strength, while an Altman Z-Score of 4.3 places the firm in a safe zone away from distress. Conversely, the Beneish M-Score of -2.47 indicates low probability of earnings manipulation, reinforcing confidence in the reported margins despite the company's small market capitalization relative to its sector peers.
Valuation metrics present a significant divergence between current pricing and intrinsic value estimates derived from discounted cash flow models. While the stock trades at a P/E multiple of 17.0x—substantially below the sector average of 33.9x—the DCF analysis implies a fair value of $145, suggesting the market may be underweighting future growth potential or assigning excessive risk to this specific name. The revenue growth trajectory of 12.8% YoY aligns with the implied growth assumptions required to justify such a wide gap between current multiples and theoretical fair value, yet the discount relative to peers warrants scrutiny regarding whether macro headwinds are being over-penalized in the share price or if structural barriers limit scalability compared to larger competitors.
Risk assessment highlights an asymmetric profile where downside protection appears anchored by strong profitability metrics, though liquidity constraints inherent to small-cap status remain a latent variable not captured in standard valuation models. The combination of high margins and clean earnings quality provides a defensive floor, but the absence of leverage benefits means ROE is sensitive to any erosion in operating efficiency or margin compression. Investors must weigh whether the current discount reflects temporary sentiment-driven dislocation or persistent structural challenges that could prevent the realization of the $145 fair value target.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 6.8% | 8.8% | 10.8% |
|---|---|---|---|
| 2% | $185 | $126 | $94 |
| 3% | $230 | $145 | $104 |
| 4% | $307 | $172 | $117 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=8.8%, terminal growth 3%. Fair value $145 (+0.0%). Not investment advice.
Valuation Context
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like SLYG or SPSM, the fund manager is mechanically forced to buy or sell CVSA shares regardless of Covista Inc.'s individual fundamentals. We estimate $138M of passive capital is structurally linked to CVSA through 7 tracked ETFs. Passive flows have a limited but growing influence on CVSA's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 7 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in Covista Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If Covista Inc. (CVSA) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Amazon.com Inc. (AMZN) as the most exposed collateral stock, sharing 1 ETFs with CVSA. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 7 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
CVSA Ownership Dynamics
ETFs with Highest CVSA Exposure
Float lock-up computed from 7 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
CVSA Capital Efficiency
How efficiently does Covista Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
Covista Inc. converts 67% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 3.3% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-12 | 200 | $130.23 | $26,046 |
| 2026-05-11 | 29,432 | $133.73 | $3.9M |
| 2026-04-27 | 4 | $107.63 | $430.52 |
| 2026-04-20 | 100 | $117.91 | $11,791 |
| 2026-04-06 | 4 | $117.90 | $471.6 |
| 2026-03-31 | 673 | $114.03 | $76,742.19 |
| 2026-03-23 | 3 | $106.49 | $319.47 |
| 2026-03-20 | 2 | $106.98 | $213.96 |
| 2026-03-13 | 5,254 | $103.84 | $545,575.36 |
| 2026-03-10 | 509 | $103.13 | $52,493.17 |
| 2026-03-09 | 109 | $102.05 | $11,123.45 |
| 2026-03-04 | 9,070 | $102.70 | $931,489 |
| 2026-02-27 | 315 | $98.76 | $31,109.4 |
| 2026-02-25 | 969 | $99.59 | $96,502.71 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare CVSA to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.